Inventiva S.A.
IVADrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Sep 25, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
IVA Earnings Report
EPS Est: $-0.20 | FQ end 2026-06
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Inventiva S.A.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Inventiva S.A.'s (IVA) pipeline across Phase 3, Phase 2. Its lead program is IVA337 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Inventiva S.A.'s next FDA catalyst?→
Inventiva S.A.'s (IVA) next tracked catalyst is a Earnings expected September 25, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IVA biotech catalysts?→
Add IVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inventiva S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.